2. Biktarvy

Biktarvy has a peak sales estimate of $6 billion, according to analysts. (Gilead Sciences)

Company: Gilead Sciences
Used for: HIV
2019 sales: $4.74 billion

When Gilead Sciences' next-gen HIV therapy Biktarvy was approved in early 2018, analysts pegged it as a megablockbuster right out of the gate. There was one catch: Gilead would have to compete with GlaxoSmithKline and its two-drug combo challengers, but so far so good. And in 2020—at the least—Biktarvy is expected to add to its war chest. 

Biktarvy's sales could increase by $1.6 billion in 2020, taking its 2019 haul of $4.74 billion up to roughly $5.34 billion, according to EvaluatePharma. 

To reach its $6 billion in peak sales estimate, Gilead had a simple plan for Biktarvy, a three-drug combination of novel integrase inhibitor bictegravir with Gilead's Descovy (emtricitabine and tenofovir alafenamide): Target new patients and switch patients over from older Gilead drugs.

Just two years into the launch, that approach has worked wonders. Biktarvy scored more than $1.5 billion in sales in the fourth quarter alone—blowing away Street estimates of $1.2 billion. As of March, Biktarvy had reached nearly 2 million total prescriptions, according to RBC Capital Markets analyst Brian Abrahams, with 4.8% growth week over week. 

On the whole, Gilead's entire HIV portfolio hit $16.4 billion in sales in 2018. 

RELATED: GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth

2. Biktarvy

Suggested Articles

Eli Lilly has refocused around new medicines and met many of its compensation targets in 2019, the company said in a proxy filing.

The big names always turn up near the top of yearly sales rankings and this year is no different. Many companies on this list have faced big patent losses in…

This year looks like the end of the line for some of the biggest brands in the pharma industry.